Quarterly report [Sections 13 or 15(d)]

Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)

v3.25.1
Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)
1 Months Ended 12 Months Ended
Aug. 31, 2024
GBP (£)
Jun. 30, 2024
GBP (£)
Dec. 31, 2023
GBP (£)
Sep. 30, 2023
GBP (£)
Jun. 30, 2023
GBP (£)
Dec. 31, 2024
GBP (£)
Mar. 31, 2025
USD ($)
Apr. 06, 2023
USD ($)
Apr. 06, 2023
GBP (£)
Revenue                  
Aggregate amount of the transaction price that is allocated to performance obligations             $ 121,973,000    
GSK Termination and Transfer Agreement                  
Revenue                  
Aggregate amount of the transaction price that is allocated to performance obligations             23,007,000    
Upfront payment received | £         £ 7,500,000        
Milestone payment | £ £ 1,500,000 £ 6,000,000 £ 12,000,000 £ 3,000,000   £ 12,000,000      
Amount of transaction price of the agreement at inception               $ 37,335,000  
Upfront and milestone payment receivable | £                 £ 30,000,000
IGNYTE                  
Revenue                  
Aggregate amount of the transaction price that is allocated to performance obligations             7,778,000    
LTFU                  
Revenue                  
Aggregate amount of the transaction price that is allocated to performance obligations             $ 15,229,000